
Mattia Galli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9052590/publications.pdf Version: 2024-02-01



Μάττια Ολιιί

#	Article	IF	CITATIONS
1	Role of platelet function and genetic testing in patients undergoing percutaneous coronary intervention. Trends in Cardiovascular Medicine, 2023, 33, 133-138.	4.9	21
2	Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 20-27.	3.0	14
3	Duration of dual antiplatelet therapy and subsequent monotherapy type in patients undergoing drug-eluting stent implantation: a network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 56-64.	3.0	17
4	Efficacy and safety of dual-pathway inhibition in patients with cardiovascular disease: a meta-analysis of 49 802 patients from 7 randomized trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 519-528.	3.0	13
5	Focus on the road to modelling cardiomyopathy in muscular dystrophy. Cardiovascular Research, 2022, 118, 1872-1884.	3.8	1
6	Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment. Journal of Thrombosis and Thrombolysis, 2022, 53, 495-498.	2.1	5
7	Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 677-686.	3.0	45
8	Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials. European Heart Journal, 2022, 43, 959-967.	2.2	79
9	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351.	3.4	5
10	Type 2 myocardial infarction: a diagnostic and therapeutic challenge in contemporary cardiology. Internal and Emergency Medicine, 2022, 17, 317-324.	2.0	6
11	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 728-737.	3.0	6
12	Dual antiplatelet therapy in the contemporary drug-eluting stents era: from vulnerable stents to vulnerable patients. Journal of Thrombosis and Thrombolysis, 2022, , 1.	2.1	0
13	Antiplatelet therapy after percutaneous coronary intervention. EuroIntervention, 2022, 17, e1371-e1396.	3.2	94
14	Estrategia antitrombótica óptima en SCASEST: ¿es la edad sólo un número?. , 2022, 90, 95-97.		0
15	Optimal Antithrombotic Strategy in NSTEACS: Is Age Just a Number?. , 2022, 90, 89-91.		0
16	Dual versus triple antithrombotic therapy for atrial fibrillation-ACS/PCI: One size does not fit all. Cardiovascular Revascularization Medicine, 2022, , .	0.8	0
17	Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 86-93.	3.0	34
18	Safety and efficacy of P2Y ₁₂ inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opinion on Drug Safety, 2021, 20, 9-21.	2.4	18

Mattia Galli

#	Article	IF	CITATIONS
19	Response—letter to the editor: colchicine and risk of non-cardiovascular death in patients with coronary artery disease: a pooled analysis underlying possible safety concerns. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e72-e73.	3.0	2
20	Colchicine in ischemic heart disease: the good, the bad and the ugly. Clinical Research in Cardiology, 2021, 110, 1531-1542.	3.3	22
21	Cardiovascular safety of the tyrosine kinase inhibitor nintedanib. British Journal of Clinical Pharmacology, 2021, 87, 3690-3698.	2.4	8
22	Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. Lancet, The, 2021, 397, 1470-1483.	13.7	133
23	Unmet Clinical Needs in Elderly Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Non-valvular Atrial Fibrillation. Advances in Therapy, 2021, 38, 2891-2907.	2.9	7
24	Antiplatelet therapy in percutaneous coronary intervention: latest evidence from randomized controlled trials. Current Opinion in Cardiology, 2021, 36, 390-396.	1.8	5
25	Genetic testing in patients undergoing percutaneous coronary intervention: rationale, evidence and practical recommendations. Expert Review of Clinical Pharmacology, 2021, 14, 963-978.	3.1	27
26	Do We Need to Define Therapeutic Ranges for Edoxaban Plasma Concentration?. Journal of the American College of Cardiology, 2021, 77, 3231-3232.	2.8	2
27	Dabigatran-based dual antithrombotic therapy for patients with atrial fibrillation and ST-elevation myocardial infarction undergoing percutaneous coronary intervention. EuroIntervention, 2021, 17, 443-444.	3.2	1
28	Non-opioid analgesics in patients undergoing percutaneous coronary intervention: hype or hope?. European Heart Journal, 2021, 42, 4037-4039.	2.2	2
29	Role of perilipin 2 in microvascular obstruction in patients with ST-elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 633-642.	1.0	3
30	ORal anticoagulants In fraGile patients with percutAneous endoscopic gastrostoMy and atrial fibrillation: the (ORIGAMI) study. Journal of Cardiovascular Medicine, 2021, 22, 175-179.	1.5	3
31	Guided selection of antiplatelet therapy in acute coronary syndrome: Impact on outcomes and resource utilization. International Journal of Cardiology, 2021, 345, 36-38.	1.7	7
32	Double or triple antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention: not a matter of faith. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e16-e17.	3.0	2
33	The Role of Antiplatelet Therapy in Patients With MINOCA. Frontiers in Cardiovascular Medicine, 2021, 8, 821297.	2.4	7
34	10 Pharmacodynamic profiles of aspirin versus dual-pathway inhibition with either aspirin or clopidogrel among patients with stable atherosclerotic disease. European Heart Journal Supplements, 2021, 23, .	0.1	0
35	Dual therapy with direct oral anticoagulants significantly increases the risk of stent thrombosis compared to triple therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 128-129.	3.0	19
36	Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 43-56.	3.0	26

Mattia Galli

#	Article	IF	CITATIONS
37	Aspirin in primary prevention of cardiovascular disease in the elderly. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, 6, 326-327.	3.0	2
38	Acceso radial frente a femoral y bivalirudina frente a heparina no fraccionada en pacientes vulnerables con sÃndrome coronario agudo. Revista Espanola De Cardiologia, 2020, 73, 874-876.	1.2	0
39	Efficacy and safety of novel oral anticoagulants versus low molecular weight heparin in cancer patients with venous thromboembolism: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103074.	4.4	12
40	Randomised trials and meta-analyses of double vs triple antithrombotic therapy for atrial fibrillation-ACS/PCI: A critical appraisal. IJC Heart and Vasculature, 2020, 28, 100524.	1.1	13
41	Radial versus femoral and bivalirudin versus unfractionated heparin in vulnerable patients with acute coronary syndromes. Revista Espanola De Cardiologia (English Ed), 2020, 73, 874-876.	0.6	0
42	Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace, 2020, 22, 538-546.	1.7	36
43	Stent Thrombosis With Dual Antithrombotic Therapy in Atrial Fibrillation–ACS/PCI Trials. Journal of the American College of Cardiology, 2020, 75, 1727-1728.	2.8	8
44	Recurrence of angina after ST-segment elevation myocardial infarction: the role of coronary microvascular obstruction. European Heart Journal: Acute Cardiovascular Care, 2019, , 2048872619880661.	1.0	2
45	Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction. Frontiers in Physiology, 2019, 10, 1347.	2.8	81
46	Are Atherogenic Lipoprotein Phenotype and Inflammation Indicative of Plaque Phenotype and Clinical Stability in Coronary Artery Disease?—Reply. JAMA Cardiology, 2019, 4, 951.	6.1	10
47	Sustained safe and effective anticoagulation using Edoxaban via percutaneous endoscopic gastrostomy. ESC Heart Failure, 2019, 6, 884-888.	3.1	5
48	Recurrent chest pain: â€~what is essential is invisible to the eye?'. European Heart Journal Supplements, 2019, 21, C11-C14.	0.1	0
49	Dual quantitative coronary angiography accurately quantifies intracoronary thrombotic burden in patients with acute coronary syndrome: Comparison with optical coherence tomography imaging. International Journal of Cardiology, 2019, 292, 25-31.	1.7	9
50	Coronary Atherosclerotic Phenotype and Plaque Healing in Patients With Recurrent Acute Coronary Syndromes Compared With Patients With Long-term Clinical Stability. JAMA Cardiology, 2019, 4, 321.	6.1	92
51	A case of â€~resistant' thrombus. Journal of Cardiovascular Medicine, 2019, 20, 397-399.	1.5	1
52	Early anticoagulation in the current management of NSTE-ACS: Evidence, guidelines, practice and perspectives. International Journal of Cardiology, 2019, 275, 39-45.	1.7	12
53	Dropping aspirin in patients with atrial fibrillation undergoing percutaneous coronary intervention: a jump with a weak parachute?. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 55-56.	3.0	6
54	Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nature Reviews Cardiology, 2019, 16, 113-130.	13.7	73

MATTIA GALLI

#	Article	IF	CITATIONS
55	Neoatherosclerosis after drug-eluting stent implantation: a novel clinical and therapeutic challenge. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 105-116.	3.0	44
56	Electronic Cigarettes and Cardiovascular Risk: Caution Waiting for Evidence. European Cardiology Review, 2019, 14, 151-158.	2.2	18
57	How deep is your lesion? Extreme guideliner V3 intubation through RIMA graft to treat a distal left anterior descending artery stenosis. Journal of Cardiovascular Medicine, 2018, 19, 606-608.	1.5	1
58	Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1273-1285.	3.3	6
59	High-risk percutaneous coronary intervention: how to define it today?. Minerva Cardioangiologica, 2018, 66, 576-593.	1.2	14
60	Where Does Inflammation Fit?. Current Cardiology Reports, 2017, 19, 84.	2.9	32
61	A current approach to heart failure in Duchenne muscular dystrophy. Heart, 2017, 103, 1770-1779.	2.9	75
62	Optical coherence tomography assessment and quantification of intracoronary thrombus: Status and perspectives. Cardiovascular Revascularization Medicine, 2015, 16, 172-178.	0.8	16
63	Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. European Heart Journal, 2015, 36, 1377-1384.	2.2	226
64	Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. European Heart Journal Cardiovascular Imaging, 2014, 15, 917-925.	1.2	15
65	Pancoronary plaque vulnerability in patients with acute coronary syndrome and ruptured culprit plaque: A 3-vessel optical coherence tomography study. American Heart Journal, 2014, 167, 59-67.	2.7	74
66	Intracoronary microparticles and microvascular obstruction in patients with ST elevation myocardial infarction undergoing primary percutaneous intervention. European Heart Journal, 2012, 33, 2928-2938.	2.2	95
67	Eosinophil cationic protein and clinical outcome after bare metal stent implantation. Atherosclerosis, 2011, 215, 166-169.	0.8	26
68	Feasibility and long-term safety of elective Impella-assisted high-risk percutaneous coronary intervention: a pilot two-centre study. Journal of Cardiovascular Medicine, 2008, 9, 1004-1010.	1.5	55